Corporate ActionMay 26, 2026, 06:16 AM
Editas Medicine Commences Underwritten Public Offering of Stock & Warrants
AI Summary
Editas Medicine, a pioneering gene editing company, has commenced an underwritten public offering of its common stock (or pre-funded warrants to purchase shares) and accompanying warrants. All of the securities in the offering are to be sold by Editas Medicine. Cantor and Wells Fargo Securities are serving as joint book-running managers for the proposed offering, which is subject to market and other conditions.
Key Highlights
- Editas Medicine commenced an underwritten public offering of its common stock and accompanying warrants.
- The offering includes common stock (or pre-funded warrants) and warrants to purchase shares.
- All securities in the offering are being sold by Editas Medicine.
- Cantor and Wells Fargo Securities are acting as joint book-running managers.
- The proposed offering is subject to market and other conditions.
- The securities are being offered pursuant to an effective shelf registration statement on Form S-3.
Price Impact
More from EDIT